Baidu
map

国内III期肺癌规范化诊疗示范中心正式成立,精准助力III期肺癌规范化诊疗

2019-09-27 佚名 MedSci

2019年9月14日,由中国科学院大学附属肿瘤医院(浙江省肺癌诊治技术研究中心)在全国范围内率先开设的“III期肺癌规范化诊疗示范中心”正式成立,并于9月20日正式挂牌。这是国内首个专门针对III期肺癌成立的诊疗示范中心,将会推动中国III期肿瘤的规范化诊疗进程,有效把握III期这一治疗 “关键窗口期”,助力更多的患者治愈肿瘤,重现绽放!

2019年9月14日,由中国科学院大学附属肿瘤医院(浙江省肺癌诊治技术研究中心)在全国范围内率先开设的“III期肺癌规范化诊疗示范中心”正式成立,并于9月20日正式挂牌。这是国内首个专门针对III期肺癌成立的诊疗示范中心,将会推动中国III期肿瘤的规范化诊疗进程,有效把握III期这一治疗 “关键窗口期”,助力更多的患者治愈肿瘤,重现绽放!

III期肺癌规范化诊疗示范中心成立

借“III期肺癌规范化诊疗示范中心”成立之际,中国科学院大学附属肿瘤医院陈明院长,中国科学院大学附属肿瘤医院杜向慧教授,中国科学院大学附属肿瘤医院范云教授,浙江大学医学院附属第二医院范军强教授同与会专家共同分享了III期肺癌治疗的最新进展:免疫治疗联合放化疗的探索和应用。

3前有路·聚焦III期,把握肺癌治疗的“关键窗口期”

2019年1月,国家癌症中心发布了最新一期的全国癌症统计数据。数据显示,恶性肿瘤死亡占居民全部死因的23.91%,而肺癌的发病率及死亡率分别占全部恶性肿瘤的20.03%及26.99%,是当前肿瘤防控的重点疾病。III期肺癌约占肺癌整体的20%左右,是一个不能忽视的庞大的患者群体。

III期肺癌俗称局部晚期肺癌,顾名思义,“局部”是指肿瘤仍然局限在单侧肺区,仍属于局部范围的肺癌,“晚期”则说明肺癌已经进展到了相当规模的阶段,III期肺癌是肺癌治疗的“关键窗口期”,第一是因为III期肺癌接受规范化治疗后,仍然具备治愈的机会,第二则是因为如接受了不规范的治疗,III期很容易继续进展到IV期肺癌,而IV期肺癌俗称转移性(晚期)肺癌,已经发生了骨、肝、脑等远处器官转移,属于全身范围的肺癌。

III期肺癌规范化诊疗示范中心挂牌

陈明院长指出,III期肺癌异质性极强,需要多学科综合诊疗。III期肺癌接受规范化治疗后,仍然具备治愈的机会。开设III期肺癌诊疗专场,聚焦III期,同与会专家共同探讨放疗的新突破,机会非常难得。设立III期肺癌规范化诊疗示范中心,有助于提高III期肺癌规范化诊疗新格局。

中国科学院大学附属肿瘤医院陈明院长

治疗新突破,新一代免疫疗法显著提高III期肺癌治愈率

近年来,肿瘤免疫治疗作为新兴的治疗方法,成为肿瘤治疗研究领域的一大热点。既往20年间,除了极少部分的III期肺癌患者可以手术,绝大多数的III 期肺癌常用的标准治疗手段是同步放化疗,3年生存率约为30%左右。免疫治疗的出现,给了放化疗突破瓶颈的新机会。

PACIFIC(太平洋)研究证明Durvalumab(简称“I”药)免疫治疗可以显著延长接受放化疗之后III期不可切除肺癌患者的无疾病进展生存期和总生存期。PACIFIC研究结果显示,相对于放化疗,Durvalumab(简称“I”药)巩固治疗降低了32%的死亡风险,中位无疾病进展生存期(PFS)为17.2个月,至肿瘤复发时间延长了近1年。在今年6月举办的美国临床肿瘤学会(ASCO)年会上,PACIFIC研究又公布了3年总生存率(OS)结果:57%。由于3年是免疫治疗长期生存的拐点,后续进入了长拖尾效应阶段,预期5年生存率可以达到50%,PACIFIC治疗模式改变了III期不可切除肺癌的诊疗模式,让接近1/2的III期肺癌患者治愈。美国NCCN指南已把同步放化疗加Durvalumab(简称“I”药)免疫治疗列为III期肺癌的标准治疗方案。

对此,范军强教授从外科视角谈III期肺癌的手术人群选择,表示III期N2需要多学科分析,IIIA患者需要个体化分析,大部分IIIA N2手术不可切除患者、IIIB/IIIC期患者建议同步放化疗+Durvalumab巩固治疗。范云教授从肿瘤内科视角谈免疫时代III期不可手术切除的诊疗策略,表示同步放化疗后联合Durvalumab巩固治疗是III期肺癌新的标准治疗方案。

依托医院资源优势,促进肺癌诊疗规范化

中国科学院大学附属肿瘤医院始建于1963年10月,是新中国成立最早的四所肿瘤医院之一,集肿瘤预防、医疗、科研、教学、康复于一体,承担着国家肿瘤防治重任,在全国的肿瘤防治工作中发挥着龙头作用,连续8年名列中国最佳肿瘤专科排行前十。医院学科设置齐全,单病种多学科综合诊治(MDT)模式覆盖常见病种,医疗业务量居全国肿瘤专科医院前列。值得注意的是,中国科学院大学附属肿瘤医院放疗科设备配套齐全,性能优越,拥有9台加速器、2台模拟定位CT和30余套放疗计划系统,是华东地区规模较大的放疗中心。陈明院长作为放疗科专家领路人谈放疗在肺癌的发展,表示精准放疗任重道远。

此次III期肺癌诊疗示范中心的成立将推动肺癌的多学科诊疗进程,促进各诊疗示范中心加强医生的技能培训、规范院内MDT会诊,为肺癌患者提供多方位、更有针对性的治疗方案。此外,示范中心还将促进院际交流活动,互相交流及分享诊疗经验。为后续在积累诊疗经验后开设III期肺癌门诊,提供更精准、优质的医疗服务打下夯实基础。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2034074, encodeId=bee620340e4da, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9577, encryptionId=d0f295e78b, topicName=III期肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Nov 02 05:59:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916160, encodeId=b71a191616045, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 05 03:59:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691396, encodeId=1a38169139614, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Mar 26 03:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721634, encodeId=07261e2163474, content=<a href='/topic/show?id=f66c90645be' target=_blank style='color:#2F92EE;'>#规范化诊疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90645, encryptionId=f66c90645be, topicName=规范化诊疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=272333051942, createdName=chenshujs, createdTime=Sat Jul 18 12:59:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403446, encodeId=12581403446c8, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594645, encodeId=8185159464585, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2034074, encodeId=bee620340e4da, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9577, encryptionId=d0f295e78b, topicName=III期肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Nov 02 05:59:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916160, encodeId=b71a191616045, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 05 03:59:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691396, encodeId=1a38169139614, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Mar 26 03:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721634, encodeId=07261e2163474, content=<a href='/topic/show?id=f66c90645be' target=_blank style='color:#2F92EE;'>#规范化诊疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90645, encryptionId=f66c90645be, topicName=规范化诊疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=272333051942, createdName=chenshujs, createdTime=Sat Jul 18 12:59:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403446, encodeId=12581403446c8, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594645, encodeId=8185159464585, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2020-02-05 juliusluan78
  3. [GetPortalCommentsPageByObjectIdResponse(id=2034074, encodeId=bee620340e4da, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9577, encryptionId=d0f295e78b, topicName=III期肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Nov 02 05:59:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916160, encodeId=b71a191616045, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 05 03:59:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691396, encodeId=1a38169139614, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Mar 26 03:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721634, encodeId=07261e2163474, content=<a href='/topic/show?id=f66c90645be' target=_blank style='color:#2F92EE;'>#规范化诊疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90645, encryptionId=f66c90645be, topicName=规范化诊疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=272333051942, createdName=chenshujs, createdTime=Sat Jul 18 12:59:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403446, encodeId=12581403446c8, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594645, encodeId=8185159464585, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2034074, encodeId=bee620340e4da, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9577, encryptionId=d0f295e78b, topicName=III期肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Nov 02 05:59:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916160, encodeId=b71a191616045, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 05 03:59:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691396, encodeId=1a38169139614, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Mar 26 03:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721634, encodeId=07261e2163474, content=<a href='/topic/show?id=f66c90645be' target=_blank style='color:#2F92EE;'>#规范化诊疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90645, encryptionId=f66c90645be, topicName=规范化诊疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=272333051942, createdName=chenshujs, createdTime=Sat Jul 18 12:59:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403446, encodeId=12581403446c8, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594645, encodeId=8185159464585, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2034074, encodeId=bee620340e4da, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9577, encryptionId=d0f295e78b, topicName=III期肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Nov 02 05:59:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916160, encodeId=b71a191616045, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 05 03:59:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691396, encodeId=1a38169139614, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Mar 26 03:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721634, encodeId=07261e2163474, content=<a href='/topic/show?id=f66c90645be' target=_blank style='color:#2F92EE;'>#规范化诊疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90645, encryptionId=f66c90645be, topicName=规范化诊疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=272333051942, createdName=chenshujs, createdTime=Sat Jul 18 12:59:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403446, encodeId=12581403446c8, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594645, encodeId=8185159464585, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2034074, encodeId=bee620340e4da, content=<a href='/topic/show?id=d0f295e78b' target=_blank style='color:#2F92EE;'>#III期肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9577, encryptionId=d0f295e78b, topicName=III期肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Nov 02 05:59:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916160, encodeId=b71a191616045, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Feb 05 03:59:00 CST 2020, time=2020-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691396, encodeId=1a38169139614, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Mar 26 03:59:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721634, encodeId=07261e2163474, content=<a href='/topic/show?id=f66c90645be' target=_blank style='color:#2F92EE;'>#规范化诊疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90645, encryptionId=f66c90645be, topicName=规范化诊疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=272333051942, createdName=chenshujs, createdTime=Sat Jul 18 12:59:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1403446, encodeId=12581403446c8, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594645, encodeId=8185159464585, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Sep 29 00:59:00 CST 2019, time=2019-09-29, status=1, ipAttribution=)]

相关资讯

JAMA Intern Med:肺癌筛查CT辐射剂量差异研究

研究发现,各医疗机构LCS-CT辐射剂量存在较大的差异,建立统一的指南标准将有助于减少不必要的射线暴露

Ann Oncol: 不到1分钟!电子鼻“嗅出”肺癌免疫疗法适用者,准确率达85%

免疫疗法极大地改善了晚期非小细胞肺癌(NSCLC)的治疗,但是不幸的是,它仅对一部分患者有效,这一比例约为20%。尽管免疫疗法的副作用往往比化疗要少,但大约10%的患者会产生更严重的副作用。

捷报频传!张力教授团队再次报道肺癌EGFR 20ins治疗新方案:奥希替尼+西妥昔单抗 成为潜力之选!

EGFR 突变肺癌患者中,第20号外显子插入突变,简称EGFR 20ins,占EGFR 突变的4%~12%,多见于不吸烟的NSCLC患者。

JAMA Netw Open:美国60年随访研究首次发现,儿童期接种卡介苗还能预防肺癌

我们都知道,卡介苗是预防肺结核而接种的一种疫苗,目前我国新生儿免费接种。

电子鼻“嗅出”肺癌免疫疗法适用者:不到1分钟,准确率达85%

在近两年的肺癌治疗中,PD-1免疫治疗无疑成为了新晋网红,在目前中国上市的5个PD-1药物中,其中两个进口药Opdivo(纳武利尤单抗)和Keytruda(帕博利珠单抗)都获批了非小细胞肺癌(NSCLC)的适应症,截至到目前,均已在华上市一年有余,然而根据相关报道,有知名三甲医院的肿瘤科医生表示:随着使用PD-1抑制剂治疗患者的例数增加,碰到免疫疗法带来的相关不良反应机会也开始增加了,甚至连续碰到

免疫+化疗新方案亮相世界肺癌大会,中国自主抗肿瘤科研实力不容小觑

肺癌是全球最高发的癌症,被称作头号癌症杀手。记者18日获悉,不久前在西班牙巴塞罗那举行的世界肺癌大会(WCLC)上,同济大学附属上海市肺科医院周彩存教授带来针对中国人群NSCLC(晚期/转移性非鳞状非小细胞肺癌)一线免疫联合化疗的III期临床研究的口头报告,国产免疫抑制剂的三期临床研究报告在国际舞台上亮相此前未有报道。卡瑞利珠单抗联合化疗一线治疗晚期/转移性非鳞状非小细胞肺癌(NSCLC)的随机I

Baidu
map
Baidu
map
Baidu
map